UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
Multiple Myeloma
DRUG: Ixazomib|DRUG: Pomalidomide|DRUG: Dexamethasone
Response rate after combination of Ixazomib, Pomalidomide and Dexamethasone therapy, Response rate will be assessed at baseline, with each scheduled study visit , including the exit visit., 28 days
This single arm, Phase II study will examine the efficacy and safety of the novel Proteasome/IMiD combination of Ixazomib 4mg days 1, 8, 15, Pomalidomide 4 mg days 1-21, Dexamethasone 20 mg days 1, 8, 15, and 22 of a 28 day cycle, in relapse patients. The long term aim being to develop a backbone regimen to which future novel targeted treatments may be added as part of a personalized medicine approach.